ERBB2 and triple-negative breast carcinoma: Radojicic et al. and Dong et al. only selected triple-negative breast cancer cases [24,42], Müller et al. enrolled Her2+ breast cancer patients [44], whereas other studies included mixed type of breast cancer patients.